AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Orexo Share Issue/Capital Change 2015

Jun 30, 2015

3093_rns_2015-06-30_776f0d4d-17b7-4453-9913-e607a0fc814f.pdf

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

Press release

Number of shares and votes in Orexo

Uppsala, Sweden – June 30, 2015 - The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company's incentive programs.

Today, the last trading day of the month, there are in total 34,445,810 shares and votes in the company.

For further information, please contact:

Henrik Juuel, EVP and Chief Financial Officer Tel: +46 (0)18-780 88 00, E-mail: [email protected]

About Orexo

Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for maintenance treatment of opioid dependence in the US. Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo's unique knowledge and expertise in sublingual drug delivery. R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo's share is listed on Nasdaq Stockholm Exchange Mid Cap (STO: ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo's global headquarters and R&D are based in Uppsala, Sweden.

For information about Orexo please visit www.orexo.com